Search

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Schizophrenia: Trial Results Show Advance in Cognition | BI US

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US

Read more on how the Boehringer Ingelheim mastitis grading chart protocols lead to creating better informed mastitis treatment decisions in livestock.

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge

Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US

The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

First half 2019: High levels of investment in R&D and robust organic growth

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

Boehringer Ingelheim wins 2023 Prix Galien USA

Boehringer Ingelheim wins 2023 Prix Galien USA 2023 Prix Galien USA Best Orphan/Rare Disease Solution Award

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers